Recently, the two countries have taken new steps to further deepen their cooperation in biotechnology by signing a technology transfer contract for the research, production and development of a medicine designed to treat different types of cancer.

Currently, the two countries operate three companies in Chinese territory that oversee five manufacturing plants, which incorporate Cuban technology. Over the last 20 years, they have undertaken more than 30 joint projects, including those related to monoclonal antibodies and interferons, marketed in China and other states.

In the Asian giant, various Cuban biotechnological products are present, such as Nimotuzumab, used for the treatment of pancreatic cancer. In fact, during the COVID-19 pandemic, on Chinese territory, the Interferon Alfa 2B recombinant treatment was used for individuals infected by the virus. 

Part of these advances includes the establishment of the China-Cuba Joint Innovation Center in Biotechnology in the Yongzhou Economic and Technological Development Zone. This centre is the first of its kind in the realm of scientific and technical collaboration.

The scientific cooperation between Cuba and China in the field of health is an example of collaboration between two countries that share a common vision regarding the importance of research and development in improving the health and well-being of their populations [1].

Related articles
Cuba strengthens biotech industry through Eurasian partnerships

Pharmaceutical companies in China manufacturing copy biologicals

Biosimilar monoclonal antibodies in China 

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Cuba and China strengthen scientific cooperation for the development of medical treatments [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Sep 1]. Available from: www.gabionline.net/pharma-news/cuba-and-china-strengthen-scientific-cooperation-for-the-development-of-medical-treatments

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.